IGF1 and acromegaly: Octreotide exerts its effect by inhibiting the release of pituitary and gastroenteropancreatic hormones, i.e., serum growth hormone (GH) and insulin-like growth factor 1/somatomedin C (IGF-1), which are hyperexcreted in GH-releasing hormone-secreting adenoma promoting acromegaly.